XOLAIR®

What Are XOLAIR® Indications?

XOLAIR® is indicated for:

1. Severe Persistent Asthma:
   • For adults, adolescents, and children (6 years and older) with severe persistent allergic asthma inadequately controlled with inhaled corticosteroids and long-acting beta-agonists (LABAs).
   • Patients should have a positive skin test or in vitro reactivity to a perennial aeroallergen and a baseline IgE level within the specified range for treatment.
2. Chronic Spontaneous Urticaria (CSU):
   • For adults and adolescents (12 years and older) with chronic spontaneous urticaria who remain symptomatic despite H1 antihistamine treatment.

What Are the XOLAIR® Side Effects?

Common side effects of XOLAIR® include:

• Injection Site Reactions:
  • Pain, swelling, redness, and itching at the injection site.
• Gastrointestinal Symptoms:
  • Nausea, vomiting, and diarrhea.
• Upper Respiratory Tract Infections:
  • Symptoms such as sore throat, nasal congestion, and cough.
• Headache:
  • One of the most commonly reported side effects.
• Musculoskeletal Pain:
  • Joint and muscle pain.
• Dizziness and Fatigue:
  • Patients may experience tiredness or dizziness.

Serious side effects, although rare, include:

• Anaphylaxis:
  • A severe allergic reaction that can occur after any dose of XOLAIR®, usually within 2 hours of administration but sometimes delayed.
• Thrombocytopenia:
  • Low platelet count leading to increased risk of bleeding.
• Parasitic Infections:
  • Due to its mechanism of action, XOLAIR® may increase susceptibility to certain parasitic infections.
• Malignancies:
  • There have been reports of malignancies in patients treated with XOLAIR®, though a causal relationship has not been established.

XOLAIR® Administration Technique

Administering XOLAIR® (Omalizumab) requires adherence to specific guidelines to ensure efficacy and patient safety. Below is a detailed step-by-step approach for the administration of XOLAIR®:

Preparation

1. Patient Assessment:
   • Verify the patient’s weight and baseline IgE levels to determine the appropriate dose.
   • Confirm that the patient does not have any contraindications to XOLAIR®.
2. Reconstitution:
   • XOLAIR® is supplied as a lyophilized powder that must be reconstituted with sterile water for injection.
   • Use a new vial for each injection.
   • Add the sterile water slowly to the vial and gently swirl (do not shake) until the powder is fully dissolved.
   • The solution should be clear to slightly opalescent and free from visible particulates.
   • Reconstitution typically takes 15-20 minutes.

Injection

1. Site Selection:
   • XOLAIR® is administered via subcutaneous injection.
   • Recommended injection sites include the upper arm, thigh, or abdomen. Rotate sites with each injection to avoid local irritation.
2. Dosage:
   • The dose and frequency of administration are based on the patient’s body weight and baseline IgE levels for asthma or a fixed dose for chronic spontaneous urticaria.
   • Ensure that the appropriate dose has been prepared and loaded into a syringe.
3. Injection Technique:
   • Clean the injection site with an antiseptic solution.
   • Use a new needle and syringe for each injection to maintain sterility.
   • Pinch the skin at the injection site to form a firm surface.
   • Insert the needle at a 45-degree angle into the subcutaneous tissue.
   • Inject the solution slowly and steadily until the syringe is empty.
   • Withdraw the needle and apply gentle pressure to the injection site with a sterile gauze or cotton ball to stop any bleeding.

Post-Injection

1. Observation:
   • Patients should be observed for at least 2 hours after the first three injections for signs of anaphylaxis.
   • For subsequent injections, a 30-minute observation period is recommended.
   • Have emergency medical equipment and medications, such as epinephrine, readily available in case of anaphylactic reactions.
2. Patient Education:
   • Educate patients on the signs and symptoms of anaphylaxis and instruct them to seek immediate medical attention if they experience symptoms such as rash, swelling, difficulty breathing, or dizziness.
   • Advise patients to avoid strenuous activities for 24 hours post-injection.
3. Documentation:
   • Record the date, dose, injection site, and any adverse reactions observed during the observation period in the patient’s medical record.

What is the XOLAIR® Dosing Schedule?

The dosing schedule for XOLAIR® is determined based on the condition being treated:

1. Severe Persistent Asthma:
   • Dosing is based on the patient’s body weight and baseline IgE levels.
   • Administered subcutaneously every 2 or 4 weeks.
   • Typical doses range from 75 mg to 375 mg per injection.
2. Chronic Spontaneous Urticaria (CSU):
   • A standard dose of 300 mg is administered subcutaneously every 4 weeks.
   • For some patients, a 150 mg dose every 4 weeks may be sufficient based on clinical response.

XOLAIR® Monitoring and Follow-up

• Asthma Patients:
  • Regular monitoring of asthma control and IgE levels is recommended.
  • Assess for any adverse effects or signs of anaphylaxis post-administration.
• CSU Patients:
  • Evaluate the severity and frequency of urticaria symptoms periodically.
  • Adjust dosing based on patient response and side effects.

Regular follow-up appointments are crucial to monitor the effectiveness and safety of the treatment, adjust dosing as necessary, and manage any adverse effects.